Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
To determine the serum concentrations of ranibizumab and vascular endothelial growth factor
(VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab
Phase:
N/A
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine